Cumberland Pharmaceuticals (CPIX) Cost of Revenue (2010 - 2026)

Cumberland Pharmaceuticals (CPIX) has 17 years of Cost of Revenue data on file, last reported at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 35.64% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $7.2 million (up 11.49% YoY), and the FY2025 full-year result was $6.7 million, up 1.23% from the prior year.
• Cost of Revenue eased to $1.9 million in Q1 2026, from $2.2 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $2.7 million in Q4 2022 to a low of $988760.0 in Q3 2025.
• A 5-year average of $1.8 million and a median of $1.8 million in 2023 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue surged 67.5% in 2022 and slumped 43.48% in 2023, its largest moves.
• Tracing CPIX's Cost of Revenue over 5 years: stood at $2.7 million in 2022, then tumbled by 42.27% to $1.5 million in 2023, then advanced by 29.18% to $2.0 million in 2024, then advanced by 13.4% to $2.2 million in 2025, then fell by 13.72% to $1.9 million in 2026.
• Business Quant data shows CPIX's Cost of Revenue at $1.9 million in Q1 2026, $2.2 million in Q4 2025, and $988760.0 in Q3 2025.